Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

Clinical trial NCT06932068 · RECRUITING

Trial details

NCT number: NCT06932068
Sponsor: Qilu Hospital of Shandong University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

HER2 Negative Low PD-L1 Expressing Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Start date: 2025-03-26
Primary completion: 2026-10-31
Enrollment: 77

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.